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Little is known about the clinical relevance of nontuber-
culous mycobacteria (NTM) in the Arabian Peninsula. We 
assessed the prevalence and studied a random sample of 
isolates at a reference laboratory in Muscat, Oman. NTM 
cause disease in this region, and their prevalence has in-
creased.
Nontuberculous mycobacteria (NTM) are common in-habitants of the environment and have been cultured 
from water, soil, and animal sources worldwide. NTM are 
opportunistic pathogens, mostly affecting patients with 
preexisting pulmonary disease such as chronic obstructive 
pulmonary disease or tuberculosis (TB), or those with sys-
temic impairment of immunity. The latter group includes 
those with HIV infection, those using immunosuppressive 
drugs, and those with leukemia (1).
Because NTM are common in the environment and re-
sistant to commonly used disinfectants, they can be present 
in nonsterile patient material such as sputum and contami-
nated medical equipment (bronchoscope washers or sam-
ples in the laboratory) and consequently cause pseudoin-
fection (1,2). To distinguish pseudoinfections from NTM 
disease and establish the clinical relevance of isolated 
NTM, the American Thoracic Society (ATS) has published 
diagnostic criteria (1).
Studies on the clinical relevance of NTM have tradi-
tionally been restricted to western countries, where the in-
cidence of TB is relatively low. More recently, research has 
been initiated in African and East Asian countries (1–5). 
There have been no recent reports on isolation and clinical 
relevance of NTM on the Arabian Peninsula. We analyzed 
a random sample of NTM isolated from clinical samples 
in Oman by using molecular techniques. Their clinical rel-
evance was retrospectively analyzed by applying the up-
dated ATS diagnostic criteria for NTM disease (1).
The Study
Prevalence of NTM at the Central Public Health Lab-
oratory (CPHL), the national TB reference laboratory of 
the Ministry of Health in Muscat, Oman, was assessed by 
using a laboratory database. The CPHL Institutional Re-
view Board reviewed and approved this study. The CPHL 
received 5,488 samples submitted for Mycobacterium spp. 
culture during 2006–2007. Samples were subcultured in 
Lowenstein-Jensen medium and automated Mycobacterial 
Growth Indicator Tubes (MGIT960; Becton Dickinson, 
Franklin Lakes, NJ, USA) and incubated at 36°C.  A total 
of 491 (9%) samples yielded positive cultures. M. tubercu-
losis complex bacteria were isolated from 445 (91%) sam-
ples, and NTM were isolated from 46 samples (9%). Most 
NTM were cultured from respiratory samples (sputum, n = 
36, 78%; bronchial lavage, n = 2, 4%); the remainder were 
from lymph nodes (n = 3, 6%), urine (n = 2, 4%), or other 
sources (n = 3, 6%). The percentage of NTM increased 
from 7.6% (18/235) in 2006 to 10.9% (28/256) in 2007.
Thirteen samples were randomly selected from all 
NTM isolated at CPHL during January 2006–September 
2007. Selected NTM were subjected to molecular identifi -
cation at the Dutch National Mycobacteria Reference Lab-
oratory (National Institute for Public Health and the En-
vironment, Bilthoven, the Netherlands). To identify NTM, 
after eliminating isolates of the M. tuberculosis complex 
by using the GenoType MTBC assay (Hain Lifesciences, 
Nehren, Germany), we used the Inno-Lipa Mycobacteria 
version 2 reverse line blot (Innogenetics, Ghent, Belgium). 
Both assays were used according to the manufacturer’s in-
structions. If no species-specifi c result was obtained, addi-
tional sequencing of the hypervariable region A of the 16S 
rDNA gene was performed (6).
The 13 samples were identifi ed as 9 M. avium complex 
(MAC; 3 M. intracellulare sequevars, 3 M. chimaera, 1 M. 
colombiense, 1 M. avium, and 1 untyped), 1 M. marinum, 1 
M. kansasii, 1 M. simiae, and 1 M. fl avescens (Table). One 
sample could not be identifi ed beyond the M. avium–intra-
cellulare–scrofulaceum complex level because insuffi cient 
DNA was available for further analyses. Because our mo-
lecular identifi cation method does not distinguish M. mari-
num from M. ulcerans, we performed a light exposure test, 
which identifi ed yellow colony pigmentation typical for M. 
marinum. One sample yielded M. tuberculosis and M. in-
tracellulare (Table).
We assessed the clinical relevance of isolates from 13 
patients in a retrospective study by applying ATS diagnos-
tic criteria and scoring demographic and clinical data. Re-
sults are detailed in the Table. Seven (54%) of the patients 
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were female (mean age 43 years). Eight (62%) of 13 pa-
tients met the ATS diagnostic criteria and were thus likely 
to have NTM disease. Among 9 patients with MAC iso-
lates, 6 (67%) had MAC disease. Most (11, 85%) isolates 
were cultured from pulmonary samples. Fibrocavitary and 
nodular-bronchiectatic pulmonary NTM disease were not-
ed, with a predominance of fi brocavitary disease (Table).
Information on predisposing conditions was not avail-
able for most patients, although a destroyed lung on chest 
radiographs suggested previous pulmonary disease. One 
patient was HIV positive, and another patient had a relapse 
of pulmonary NTM disease.
Eight patients began treatment, mostly with fi rst-line 
treatment for TB. Three patients with pulmonary MAC 
disease and 1 with M. marinum skin disease received regi-
mens that included macrolides, fl uoroquinolones, or both. 
Therapy resulted in clinical improvement in all but 1 pa-
tient. Most patients are still receiving treatment.
Conclusions
A total of 9% all Mycobacterium-positive cultures at 
CPHL in Muscat, Oman, yielded NTM. Although this con-
clusion is based on limited data, the prevalence of NTM 
seems to be increasing in Oman. Few studies are available, 
but this increase may be true for the entire Middle East 
region.
Eight of 13 patients met the ATS diagnostic criteria; 
this fi nding probably refl ects a selection bias because CPHL 
is a reference laboratory. Nevertheless, these fi ndings indi-
cate that NTM in Oman and throughout the Middle East 
region is a serious issue that requires attention by clinicians 
and microbiologists.
Most isolates were MAC members (9/13, 69%), a 
predominance also noted in previous studies in the United 
States, Europe, and west Asian countries (25%) (1,8), and 
South Korea (48%) (9). MAC isolates from Oman were 
mostly M. intracellulare sequevars. Infrequent isolation 
of M. avium is noteworthy, despite the small number of 
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Table. Clinical and microbiologic data for 13 patients with Mycobacterium spp. infections, Oman, 2006–2007* 
Patient
no./sex/
age, y Species
AFB
smear
Positive
cultures Source Condition Symp. 
Chest
radiograph
2007
ATS
criteria Therapy Outcome
1/F/64 M. 
intracellulare†
+ Multiple Sputum – PC, F, 
WL,CP, M 
NP Met HRZE Improved
2/M/29 MAIS complex + Single Sputum – PC, Hp, 
WL
Cavities Met HRZE Improved
3/F/31 M. chimaera‡ – Multiple Sputum – None RUL bronch. Not met None Stable
4/M/28  M. chimaera‡ + Multiple Sputum – PC, WL RUL multiple 
scars, left 
lung
destroyed, 
abscess, PT
Met SClaCip Failure 
5/M/18 16S: M.
colombiense
– Single BAL HD PC, Hp, 
CP
NP Met HRE Improved
6/M/57 16S: M.
flavescens
NP Single Urine – AP NP Not met NA NA
7/F/57 M. simiae – Single Sputum HIV PC Patchy 
opacities in 
LUL and 
lingula
Met HRE Improved
8/F/12 M. kansasii
III/IV/V
– Single Sputum – None Normal Not met NA NA
9/M/43 M. tuberculosis 
and M.
intracellulare†
+ Multiple Sputum – PC, F, 
WL, M 
Cavities NA HRZES Failure
10/F/7 M. marinum – Single Skin – Skin
lesion
NP Met ECla Improved
11/F/65 M. chimaera‡ + Multiple Sputum – PC, BA Destroyed 
left lung 
Met ClaCip Improved
12/F/83 M. avium – Single Sputum – None RUL
infiltration 
Not met NA NA
13/M/63 M. 
intracellulare†
+ Single Sputum Prior PNTM 
disease
PC, WL, 
M
Bronch., PI Met RECip Improved
*AFB, acid-fast bacilli; Symp., symptoms; ATS, American Thoracic Society; PC, productive cough; F, fever; WL, weight loss; CP, chest pain; M, 
malaise/fatigue; NP, not performed; H, isoniazid; R, rifampicin; Z, pyrazinamide; E, ethambutol; MAIS, M. avium–intracellulare–scrofulaceum; Hp, 
hemoptysis; RUL, right upper lobe of lung; LUL, left upper lobe of lung; Bronch., bronchiectasis; PT, pleural thickening; S, streptomycin; Cla, 
clarithromycin; Cip, ciprofloxacin; 16S, identified by 16S rDNA gene sequencing; BAL, bronchoalveolar lavage fluid; HD, heart disease; AP, abdominal 
pain; NA, not applicable; BA, backache; PI, parenchymal infiltration; PNTM, pulmonary nontuberculous mycobacteria.    
†Reaction with the MIN-1 probe; M. intracellulare sequevar Min-A, -B, -C, or -D. 
‡Reaction with the MIN-2 probe; M. intracellulare sequevar MAC-A, which was recently elevated to the species level (M. chimaera) (7).
isolates in the random sample. Previous North American 
studies have suggested that M. intracellulare is the more 
common pulmonary pathogen within the MAC (1). We 
identifi ed 3 pulmonary samples as MAC-A strains, which 
were recently elevated to species level as M. chimaera (7). 
Two samples were clinically relevant. Although M. chi-
maera has been assumed to be highly virulent (7), a recent 
study in Germany found only 3.3% of 90 M. chimaera iso-
lates to be clinically relevant (10).
M. colombiense was fi rst described as a causative 
agent of mostly disseminated disease in HIV patients from 
Colombia (11) and was recently isolated from a child with 
lymphadenopathy in Spain (12). Its isolation in other coun-
tries and from respiratory samples in HIV-negative patients 
has not been reported. Isolation of M. simiae is a serious 
concern because this species has been reported to be preva-
lent in the Middle East (1), and HIV-associated disease has 
been reported in the region (13).
Most patients in our study received standard treat-
ment for TB. Although treatment should be prolonged and 
pyrazinamide discontinued because of natural resistance to 
pyrazinamide in NTM, the choice of fi rst-line treatment for 
TB, without companion drugs such as macrolides or fl uo-
roquinolones, is supported by a recently published trial of 
the British Thoracic Society (14).
In summary, NTM are a serious issue in Oman and 
their prevalence may be increasing. Our random sample 
demonstrates that MAC isolates are most frequently iso-
lated. True NTM disease, on the basis of ATS diagnostic 
criteria, was diagnosed in 62% of the patients assessed. 
Isolation of NTM is clinically relevant on the Arabian Pen-
insula and warrants further study.
Acknowledgment
We thank Rina de Zwaan for excellent technical assistance.
Dr Al-Mahruqi is a staff member of the Central Public Health 
Laboratory in Muscat, Oman. Her research interests are the mo-
lecular epidemiology of TB and the clinical relevance of isolation 
of nontuberculous mycobacteria in Oman.
References
  1.  Griffi th DE, Aksamit T, Brown-Elliot BA, Catanzaro A, Daley C, 
Gordin F, et al. An offi cial ATS/IDSA statement: diagnosis, treat-
ment, and prevention of nontuberculous mycobacterial diseases. 
Am J Respir Crit Care Med. 2007;175:367–416. DOI: 10.1164/
rccm.200604-571ST
  2.  Portaels F. Epidemiology of mycobacterial diseases. Clin Dermatol. 
1995;13:207–22. DOI: 10.1016/0738-081X(95)00004-Y
  3.  Buijtels PC, Petit PL, Verbrugh HA, van Belkum A, van Soolin-
gen D. Isolation of nontuberculous mycobacteria in Zambia: eight 
case reports. J Clin Microbiol. 2005;43:6020–6. DOI: 10.1128/
JCM.43.12.6020-6026.2005
  4.  Chetchotisakd P, Kiertiburanakul S, Mootsikapun P, Assanasen S, 
Chaiwarith R, Anunnatsiri S. Disseminated nontuberculous myco-
bacterial infection in patients who are not infected with HIV in Thai-
land. Clin Infect Dis. 2007;45:421–7. DOI: 10.1086/520030
  5.  Pettipher CA, Karstaedt AS, Hopley M. Prevalence and clinical 
manifestations of disseminated Mycobacterium avium complex 
infection in South Africans with acquired immunodefi ciency syn-
drome. Clin Infect Dis. 2001;33:2068–71. DOI: 10.1086/323979
  6.  Kirschner P, Springer B, Vogel U, Meier A, Wrede A, Kiekenbeck 
M, et al. Genotypic identifi cation of mycobacteria by nucleic acid 
sequence determination: report of a 2-year experience in a clinical 
laboratory. J Clin Microbiol. 1993;31:2882–9.
  7.  Tortoli E, Rindi L, Garcia MJ, Chiaradonna P, Dei R, Garzelli C, et 
al. Proposal to elevate the genetic variant MAC-A, included in the 
Mycobacterium avium complex, to species rank as Mycobacterium 
chimaera sp. nov. Int J Syst Evol Microbiol. 2004;54:1277–85. DOI: 
10.1099/ijs.0.02777-0
  8.  Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VØ, 
Curcio M, Fauville-Dufaux M, et al. Non-tuberculous mycobacte-
ria: patterns of isolation. A multi-country retrospective survey. Int J 
Tuberc Lung Dis. 2004;8:1186–93.
  9.  Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clini-
cal signifi cance of nontuberculous mycobacteria isolated from respi-
ratory specimens in Korea. Chest. 2006;129:341–8. DOI: 10.1378/
chest.129.2.341
10.  Schweickert B, Goldenberg O, Richter E, Göbel UB, Petrich A, Bu-
chholz P, et al. Occurrence and clinical relevance of Mycobacterium 
chimaera sp. nov., Germany. Emerg Infect Dis. 2008;14:1443–6. 
DOI: 10.3201/eid1409.071032
11.  Murcia MI, Tortoli E, Menendez MC, Palenque E, Garcia MJ. My-
cobacterium colombiense sp. nov., a novel member of the Myco-
bacterium avium complex and description of MAC-X as a new ITS 
genetic variant. Int J Syst Evol Microbiol. 2006;56:2049–54. DOI: 
10.1099/ijs.0.64190-0
12.  Esparcia O, Navarro F, Quer M, Coll P. A case of lymphadenopa-
thy caused by Mycobacterium colombiense. J Clin Microbiol. 
2008;46:1885–7. DOI: 10.1128/JCM.01441-07
13.  Al-Abdely HM, Revankar SG, Graybill JR. Disseminated My-
cobacterium simiae infection in patients with AIDS. J Infect. 
2000;41:143–7. DOI: 10.1053/jinf.2000.0700
14.  Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith 
AP. Clarithromycin vs ciprofl oxacin as adjuncts to rifampicin and 
ethambutol in the treatment of opportunist mycobacterial pulmo-
nary diseases and an assessment of the value of immunotherapy 
with Mycobacterium vaccae: a pragmatic, randomised trial by The 
British Thoracic Society. Thorax. 2008;63:627–34. DOI: 10.1136/
thx.2007.087999
Address for correspondence: Jakko van Ingen, National Institute for 
Public Health and the Environment, Postbak 22, National Mycobacteria 
Reference Laboratory, PO Box 1, 3720 BA Bilthoven, the Netherlands; 
email: jakko.van.ingen@rivm.nl
DISPATCHES
294 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 2, February 2009
